Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Pharmaceutical latest

EMA ETF offers scientific advice for antimicrobial resistance
2025-11-21T16:20:00+00:00
SME1: Regulatory updates for SMEs, academia and start-ups
2025-11-18T09:59:00+00:00
PS2: Navigating the green horizon – Environmental sustainability and regulatory affairs
2025-11-18T09:58:00+00:00
PS1: Tailored development of biosimilars without efficacy and safety studies – Is this the future?
2025-11-18T09:58:00+00:00
HM10: Strengthening Europe’s clinical trials competitiveness
2025-11-18T09:58:00+00:00
HM9: From barrier to bridge – Practical strategies for successful advanced therapy medicinal product (ATMP) development
2025-11-18T09:57:00+00:00

HM8: ePI is on FHIR – Preparing for implementation
2025-11-18T09:57:00+00:00
HM7: First experiences with the HTA Regulation
2025-11-18T09:57:00+00:00
HM3: Applying Artificial Intelligence in real life
2025-11-18T09:44:00+00:00
HM2: Fireside chat
2025-11-18T09:44:00+00:00
November 2025 – Contents: Human medicines sessions
2025-11-17T15:42:00+00:00
Regulatory Rapporteur November 2025 – Contents
2025-11-17T15:09:00+00:00
TOPRA Symposium 2025: Leading with impact
2025-11-17T14:01:00+00:00
HM6: How Artificial Intelligence is transforming regulatory approaches towards chemistry, manufacturing and controls (CMC)
2025-11-13T14:35:00+00:00
HM5/MD1/IVD1: Programme COMBINE – Accelerating clinical trials and medical innovation in the EU
2025-11-13T12:50:00+00:00
EMA launches #HealthNotHype campaign
2025-10-24T16:28:00+01:00
Probiotics as nutraceuticals: Bridging science, health and regulation
2025-10-10T11:16:00+01:00
The use of prior knowledge and platform approaches in early vaccine development
2025-10-10T11:15:00+01:00

More pharmaceutical content